

Date-August 14, 2025

To BSE Ltd. P. J. Towers Dalal Street. Mumbai - 400 001.

BSE Scrip Code: 524444

Subject: Outcome of the Board Meeting held on August 14, 2025

Dear Sir,

In compliance with Regulation 30 of the SEBI (LODR), Regulations, 2015 this is to inform you that at the Board Meeting of Evexia Lifecare Limited held today i.e. August 14, 2025, the Board of Directors of the company approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended on June 30, 2025.

We enclose herewith the following:

- 1) Standalone Unaudited Financial Results for the guarter ended June 30, 2025 & Limited Review Report by Statutory Auditor on Standalone Unaudited Financial Results for the quarter ended June 30, 2025.
- 2) Consolidated Unaudited Financial Results for the guarter ended June 30, 2025 & Limited Review Report by Statutory Auditor on Consolidated Unaudited Financial Results for the quarter ended June 30, 2025.

The Board Meeting started at 03:30 p.m. and ended at 04:45 p.m.

This is for your information and records.

Thanking You,

Yours faithfully,

FOR EVEXIA LIFECARE LIMITED

JAYESH RAICHANDBHAI THAKKAR **CHAIRMAN & MANAGING DIRECTOR**

DIN: 01631093

M. A. Shah & Co.

Chartered Accountants (FRN: 0112630W) Web: www.mashahca.com



Navaliwala Building, Station Road. Anand, Gujarat, 388001 Phone: +91-9904725572 E-mail: anand@prameshca.com

Limited Review Report on Un-Audited Standalone Quarterly Financial Results of Evaxia Lifecare Limited pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 for the Quarter ended on June 30, 2025.

To

Board of Directors of Evexia Lifecare Limited

INTRODUCTION

- 1. We have reviewed the accompanying statement of Un-Audited Standalone Financial Results of Evexia Lifecare Limited ("the Company") for the Quarter ended on June 30, 2025, and year to date results for the period from April 01, 2025 to June 30, 2025 ("the Statement") attached herewith. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared pursuant to the requirements Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.



SCOPE OF REVIEW

3. We conducted our review in accordance with the Standards on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

CONCLUSION

4. Based on our review conducted as stated in above Paragraph, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard ("Ind AS") specified under section 133 of the Companies Act, 2013 as amended read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in the terms of Listing Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 14th August 2025

Place: Anand

For, M. A. Shah & Co.

Chartered Accountants

FRN: 0112630W

Parag Patel, FCA

(Partner)

Mem. No.: 155916

UDIN: 25155916BMJAMI3300

ANAND

EVEXIA LIFECARE LIMITED

(CIN:L23100GJ1990PLC14692)

(Regd. Office: Vill: Tundao, Tal - Savli, Vadodara, Gujarat, India - 391775)

E-mail id: info@evexialifecare.com

Phone: 0265-2362200 / 1100

(Rs. In Lakhs Except EPS and Face Value of \$hare)

STATEMENT OF UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED ON JUNE 30, 2025

Ouarter Ended Year Ended **Particulars** June 30, 2025 March 31, 2025 June 30, 2024 March 31, 2025 **Un-Audited** Audited **Un-Audited** Audited Revenue from operations 2,041.87 2,065.80 1,517.93 8,388.68 II Other Income 3.41 13.65 III Total Revenue (I+II) 2,065.80 1,521.34 2,042.10 8,402.33 IV **Expenses** Cost of material consumed (258.15)10.50 6.51 1,731.52 Purchase of stock in trade 1,981.41 1,944.52 8,153.60 Changes in inventories of Finished Goods. (47.46)(40.67)(0.25)(162.48)Work-in-Progress and Stock-in-trade Employee benefits expenses 16.98 73.72 19.77 18.26 Finance Costs 0.69 31.21 0.01 36.16 Depreciation and amortization expense 11.91 47.15 10.12 23.23 Other Expenses 22.96 57.11 127.29 **Total Expenses** 1.986.49 1,556.46 2,006.39 8,281.95 Profit before exceptional and 79.31 -35.12 35.71 120.38 extraordinary items and tax (III-IV) VI Exceptional Items VII Profit before extraordinary items and tax 79.31 -35.12 35.71 120.38 (V-VI) Extraordinary items VIII Profit before tax (VII-VIII) TX 79.31 -35.12 35.71 120.38 Tax Expenses 1) Current tax 20.62 (7.08)(9.28)26.59 2) Deferred tax 3) Short / (Excess) Provision of Income Tax of 21.00 21.00 Previous Years Profit (Loss) for the period from 58.69 -49.0426.43 72.79 continuing operations (IX-X) XII Profit / (Loss) from discontinuing operations XIII Tax expenses of discontinuing operations XIV Profit / (Loss) from discontinuing operations (after tax) (XII-XIII) χV Net Profit / (Loss) for the period 58.69 -49.04 26.43 72.79 (XI+XIV) Other Comprehensive income A) (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to items that will not be reclassified to profit or loss B) (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss XVII **Total Comprehensive Income** 58.69 (49.04)72.79 26.43 XVIII Paid up Equity Share Capital (Face Value 18,773,29 18,773.29 10,415.68 18,773.29 Rs. 1/- each) XIX Other Equity excluding Revaluation Reserve XX Earning per share 1) Basic 0.003 -0.00260.003 0.01 2) Diluted 0.003 -0.0026 0.003 0.01

For EVEXIA LIFECARE LIMITED

adleen

DATE: 14/08/2025 PLACE: Vadodara CHAIRMAN & MANAGING DIRECTOR

DIN: 01631093

Notes on Standalone financial results- Q1 FY 25-26

- (1) The above financial results for the quarter ended on 30th June 2025 were reviewed and recommended by the audit committee and thereafter approved by Board of Directors at their respective meetings held on 14th August 2025 at Vadodara.
- (2) The statutory auditors have performed a "limited review" of the above financial results for the guarter ended on 30th June 2025.
- (3) The financial results of company have been prepared in accordance with Indian accounting standard prescribed under section 133 of the Companies Act 2013 read with relevant thereunder and in terms with regulation 33 of SEBI (LODR), 2015 and SEBI Circular dated 5th July 2016.
- (4) Previous quarter's figure have been re-grouped/ re-classified, wherever necessary to confirm to current period classification. The figures for quarter ended 31-03-2025 are balancing figures between audited figures in respect of the full financial year and unaudited published year to date figures upto the third quarter of respective financial year.

For Evexia Lifecare Limited

Jayesh Raichandbhai Thakkar Chairman & Managing Director

DIN:- 01631093

Date :- 14/08/2025 Place:- Vadoadara



Navaliwala Building, Station Road, Anand, Gujarat, 388001 <u>Phone:</u> +91-9904725572 E-mail: anand@prameshca.com

Limited Review Report on Un-Audited Consolidated Quarterly Financial
Results of Evaxia Lifecare Limited pursuant to the Regulation 33 of the SEBI
(Listing Obligation and Disclosure Requirement) Regulations, 2015 for the
Quarter ended on June 30, 2025.

To

Board of Directors of Evexia Lifecare Limited

INTRODUCTION

- 1. We have reviewed the accompanying statement of Un-Audited Consolidated Financial Results of **Evexia Lifecare Limited** ("the Company") for the Quarter ended on June 30, 2025, and year to date results for the period from April 01, 2025 to June 30, 2025 ("the Statement") attached herewith. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared pursuant to the requirements Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.



SCOPE OF REVIEW

3. We conducted our review in accordance with the Standards on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

CONCLUSION

4. Based on our review conducted as stated in above Paragraph, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard ("Ind AS") specified under section 133 of the Companies Act, 2013 as amended read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in the terms of Listing Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 14th August 2025

Place: Anand

For, M. A. Shah & Co.

Chartered Accountants

Smunn

FRN: 0112630W

Parag Patel, ECA

(Partner)

Mem. No.: 155916

UDIN: 25155916BMJAMJ5103

EVEXIA LIFECARE LIMITED

(CIN:L23100GJ1990PLC14692)

(Regd. Office: Vill: Tundao, Tal - Savli, Vadodara, Gujarat, India - 391775)

E-mail id: info@evexialifecare.com

Phone: 0265-2362200 / 1100

STATEMENT OF UN-AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED ON JUNE 30, 2025

(Rs. In Lakhs Except EPS and Face Value of Share)

	Particulars	Quarter Ended			Year Ende
		June 30, 2025 Un-Audited	March 31, 2025 Audited	June 30, 2024 Un-Audited	March 31, 2025
I	Revenue from operations	2,209.32	2,361.19	2,122.79	11,048.3
II	Other Income	-	-	13.26	14.4
III	Total Revenue (I+II)	2,209.32	2,361.19	2,136.05	11,062.77
IV	Expenses				
	Cost of material consumed	-	208.16	10.50	6.5
	Purchase of stock in trade	2,067.31	1,805.58	2,035.52	9,070.4
	Changes in inventories of Finished Goods, Work-in-Progress and Stock-in-trade	(39.67)	(343.57)	(3.01)	(192.76
	Employee benefits expenses	38.16	220.87	18.26	577.8
	Finance Costs	0.69	40.54	0.38	108.6
	Depreciation and amortization expense	21.33	46.28	10.12	169.6
	Other Expenses	35.72	339.02	31.69	1,178.8
	Total Expenses	2,123.54	2,316.88	2,103.47	10,919.12
V	Profit before exceptional and extraordinary items and tax (III-IV) Exceptional Items	85.78	44.31	32.58	143.65
VII		85.78	44.31	32.58	143.6
VIII	,	-	-		
IX	Profit before tax (VII-VIII)	85.78	44.31	32.58	143.6
X	Tax Expenses				
	1) Current tax	(22.30)	(10.40)	(8.47)	26.5
	2) Deferred tax		-		
	Short / (Excess) Provision of Income Tax of Previous Years	-	24.02		24.0
XI	continuing operations (IX-X)	63.48	30.69	24.11	93.0
	operations				
XIII	Tax expenses of discontinuing operations				
XIV	(after tax) (XII-XIII)		-		
XVI	Net Profit / (Loss) for the period (XI+XIV) Other Comprehensive income	63.48	30.69	24.11	93.04
	A) (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to items that will not be reclassified to profit or loss				
	loss (ii) Income tax relating to items that will be				
XVII	reclassified to profit or loss Total Comprehensive Income	63.48	30.69	24.11	93,04
VIII	Paid up Equity Share Capital (Face Value	18,773.29	18,773.29	10,415.68	18,773.29
XIX	Rs. 1 /- each) Other Equity excluding Revaluation		///	20,120100	20,7,512
	Reserve				
XX	Earning per share				
	1) Basic	0.03	0.00	0.02	0.0
	2) Diluted	0.03	0.00	0.02	0.0

DATE: 14/08/2025 PLACE: Vadodara 2 recen

For EVEXIA LIFECARE LIMITED

CHAIRMAN MANAGING DIRECTOR DIN: 01631093

VADODARA

Notes on Consolidated financial results- 01 FY 25-26

- (1) The above financial results for the quarter ended on 30th June 2025 were reviewed and recommended by the audit committee and thereafter approved by Board of Directors at their respective meetings held on 14th August 2025 at Vadodara.
- (2) The statutory auditors have performed a "limited review" of the above financial results for the quarter ended on 30th June 2025.
- (3) The financial results of company have been prepared in accordance with Indian accounting standard prescribed under section 133 of the Companies Act 2013 read with relevant thereunder and in terms with regulation 33 of SEBI (LODR), 2015 and SEBI Circular dated 5th July 2016.
- (4) Previous quarter's figure have been re-grouped/ re-classified, wherever necessary to confirm to current period classification. The figures for quarter ended 31-03-2025 are balancing figures between audited figures in respect of the full financial year and unaudited published year to date figures upto the third quarter of respective financial year.

For Evexia Lifecare Limited

auceen

VADODAR

Jayesh Raichandbhai Thakkar **Chairman & Managing Director**

DIN:- 01631093

Date :- 14/08/2025 Place:- Vadoadara